RxDoctor Payments Data

David Meinbach, MD

Urology · Palm Springs, FLNPI 1962596445

Payments from drug & device makers

$7,257in general payments, 2019–2025

Across 307 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$880
  • AbbVie$737
  • Endo Pharmaceuticals Inc.$519
  • Coloplast$354
  • Endo USA, Inc.$279
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1162%
  • Food & beverage$6,55090%
  • Education$5918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,257 in reported general payments places this provider in the 65th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$630,117
Medicare patients
1,216
Services billed
26,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide41$642,045
MyrbetriqMirabegron229$209,593
GemtesaVibegron86$88,760
Mirabegron ErMirabegron28$19,082
Tamsulosin Hcl1,065$16,364
Methenamine Hippurate133$11,285
Finasteride419$5,509
Solifenacin Succinate129$5,193
Testosterone43$5,056
Trospium Chloride95$4,701
Estradiol72$3,309
Silodosin27$3,286
Dutasteride54$2,280
Alfuzosin Hcl ErAlfuzosin Hcl94$1,780
Testosterone Cypionate56$1,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,229$851,638270 claims
Sumitomo Pharma America, Inc.Gemtesa$65$88,76086 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 urology providers in Florida.

Other urology in Palm Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →